Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | ACR | P10323 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | THRB | P10828 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CDH1 | P12830 | 1/20 | 0.57 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.57 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29197994 | 0.88 | ACR (0.60) | POLBACRSMN1; SMN2MAPTTHRB | |
| SCHEMBL1686327 | 0.86 | NOTUM (0.73) | POLBACRSMN1; SMN2MAPTTP53 | |
| SCHEMBL1686476 | 0.86 | MAPT (0.72) | POLBACRSMN1; SMN2MAPTTHRB | |
| SCHEMBL27237216 | 0.86 | ACR (0.58) | POLBACRSMN1; SMN2MAPTTHRB | |
| SCHEMBL1686391 | 0.86 | TP53 (0.62) | POLBACRSMN1; SMN2MAPTTP53 | |
| SCHEMBL11902914 | 0.85 | ACR (0.58) | POLBACRMAPTTHRBTP53 | |
| SCHEMBL768649 | 0.85 | ACR (0.63) | ACRSMN1; SMN2MAPTTP53L3MBTL1 | |
| SCHEMBL1227407 | 0.85 | L3MBTL1 (0.73) | ACRMAPTTHRBTP53L3MBTL1 | |
| SCHEMBL13361728 | 0.84 | ACR (0.57) | POLBACRMAPTTHRBTP53 | |
| SCHEMBL15468398 | 0.84 | MAPT (0.68) | ACRSMN1; SMN2MAPTTHRBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | IPS HEART | 2021-02-25 | — | — | US | disclosed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | disclosed |
| US-8211927-B2 | 5-phenyl-isoxazole-3-carboxamide derivatives as TRPV1 modulators | MSD, Oss B.V. (NL) | 2012-07-03 | — | — | US | disclosed |
| EP-2185530-B1 | 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS | ORGANON NV (NL) | 2011-09-14 | — | — | EP | disclosed |
| US-20110065764-A1 | 5- PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS | N.V. Organon and Pharmacopeia, LLC (NL) | 2011-03-17 | — | — | US | disclosed |
| EP-2185530-A1 | 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS | N.V. Organon (NL) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016241-A1 | 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS | N.V. ORGANON (NL) | 2009-02-05 | — | — | WO | disclosed |
| US-4774253-A | ETHER,-ACIDS, ESTERS OR AMIDES | HOFFMANN-LA ROCHE INC. (US) | 1988-09-27 | — | — | US | disclosed |
| US-4322429-A | Isoxazolylbenzamides as insecticides | ELI LILLY AND COMPANY (US) | 1982-03-30 | — | — | US | disclosed |
| EP-0048162-A1 | Isoxazolylbenzamides | ELI LILLY AND COMPANY (US) | 1982-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | POLB 3300/4885ACR 4288/4885SMN1; SMN2 14/4885 |
| US-20110065764-A1 | 5- PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS | TRPV1, TRPV5, TRPV3 | POLB 4766/4885ACR 3371/4885SMN1; SMN2 3151/4885 |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | EXOSC5, UTRN, EXOSC4 | POLB 3846/4885ACR 4094/4885SMN1; SMN2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.